What is claimed is:

- 1. An anti-coagulant comprising a polysaccharide obtained by using a raw material of a polysaccharide having a structural unit in which an abundance ratio of glucose, glucuronic acid and rhamnose is 2 : 1 : 1 mole to sulfate 8 to 80 % of a hydroxyl group contained in the above raw material polysaccharide or a compound having the sulfated polysaccharide as a partial structure.
- 2. The anti-coagulant as described in claim 1, wherein the 10 raw material polysaccharide is a polysaccharide having a structural unit represented by the following Formula (1):

- 3. The anti-coagulant as described in claim 1, wherein the raw material polysaccharide is gellan.
- 4. The anti-coagulant as described in claim 1, comprising the polysaccharide obtained by sulfating 20 to 50 % of a hydroxyl group contained in the raw material polysaccharide or the compound having the sulfated polysaccharide as a partial structure.
- 5. The anti-coagulant as described in claim 1, wherein the sulfated polysaccharide has a mean molecular weight of 1 to 1000 KDa.
 - 6. The anti-coagulant as described in claim 1, wherein the sulfated polysaccharide has a mean molecular weight of 1 to

30 KDa.

- 7. An anti-thrombus agent comprising the anti-coagulant as described in any of claims 1 to 6.
- 8. The anti-thrombus agent as described in claim 7, capable of being used for prevention and treatment of myocardial infarction, cerebral infarction or venous thrombosis.
- 9. The anti-thrombus agent as described in claim 7 or 8, obtained by processing the anti-coagulant into the form of a unit preparation for intravenous administration, intestinal
- 10 administration or oral administration.
 - 10. A blood contact face-treating agent for medical equipment, comprising the anti-coagulant as described in any of claims 1 to 6.
- 11. Medical equipment treated using the blood contact face-15 treating agent as described in claim 10.
 - 12. A catheter, an injector for collecting blood, an artificial organ, an infusion pack or an infusion tube treated using the blood contact face-treating agent as described in claim 10.